✦ LIBER ✦

Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors

✍ Scribed by Schöffski, P; Garfield, D H; Hercbergs, A; Wolter, P

Book ID: 110000424
Publisher: Nature Publishing Group
Year: 2010
Tongue: English
Weight: 105 KB
Volume: 102
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6605628

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Reply: Ongoing under-reporting of clinic

Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors

✍ Novello, S; Scagliotti, G V; Rosell, R; Socinski, M A; Brahmer, J; Atkins, J; Pa 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 72 KB

Phase I study of PKC412, a protein kinas

Phase I study of PKC412, a protein kinase C inhibitor, in combination with gemcitabine and cisplatin: Preliminary report of an ongoing phase I study

✍ Monnerat, C; Henriksson, R; Raymond, E; Berthaud, P; Vicente-Azevedo, J; Laveniu 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 106 KB

A Phase II Safety and Efficacy Study of

A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer

✍ Pili, Roberto; Qin, Rui; Flynn, P.J.; Picus, Joel; Millward, Michael; Ho, Wing M 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 791 KB

Phase II Study of Cediranib, an Oral Pan

Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

✍ Batchelor, T. T.; Duda, D. G.; di Tomaso, E.; Ancukiewicz, M.; Plotkin, S. R.; G 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 107 KB

A phase II study of lapatinib, a dual EG

A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer

✍ Whang, Young E.; Armstrong, Andrew J.; Rathmell, W. Kimryn; Godley, Paul A.; Kim 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 220 KB

Efficacy and safety of erlotinib HCl, an

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

✍ A.N. GORDON; N. FINKLER; R.P. EDWARDS; A.A. GARCIA; M. CROZIER; D.H. IRWIN; E. B 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB